Short answer
BridgeBio Pharma, Inc. (BBIO) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $195M (up 66.8% year over year) with net income of −$164M.
Q1 2026 key financials · XBRL
- Revenue
- $195M
- +66.8% YoY
- Net income
- −$164M
- +2.0% YoY
- Operating margin
- -54.5%
- EPS (diluted)
- −$0.84
- +4.5% YoY
Source: XBRL data from the BridgeBio Pharma, Inc. (BBIO) Q1 2026 10-Q on SEC EDGAR. USD.
BridgeBio Pharma, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $194.5M, up $77.9M YoY from $116.6M
- Best product line Attruby, net product revenue $180.6M vs $36.7M YoY
- Net loss $166.6M vs $169.6M; operating margin -54.5% vs -89.5% YoY
- Cash, equivalents and securities $940.2M vs $587.5M; net proceeds $619.3M from 2033 Notes
- Outlook: continued operating and net losses for at least several years; up to $500.0M stock repurchase authorization
Risk Factors
- Notes conversion risk: 2027 and 2031 Notes became convertible April 1–June 30, 2026, potentially reducing liquidity through cash settlements
- Royalty covenant risk: European royalty payments equal 60% of the first $500.0 million of annual BEYONTTRA sales
- Regulatory compliance risk: Attruby Funding Agreement royalty rate may increase from 5% to 10% in 2027
- Capital-markets risk: ATM equity program permits sales of up to $450.0 million, creating potential shareholder dilution
- Ownership concentration risk: Beneficial stockholders, directors, and executives control 40.4% of outstanding common stock
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other BridgeBio Pharma, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.